Please assess the completion status of the following clinical trial:

Trial Title: Ambien CR For Treatment Of Insomnia Associated With Depression When Used Concomitantly With Lexapro

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
MAJOR INCLUSION CRITERIA:~1. Must experience sleep disturbances at least 3 nights/week, based on historical data~2. Must meet the diagnostic requirements for Major Depressive Disorder~3. Must have QIDS-SR16 score between 6 and 15~4. Must be either newly diagnosed or show symptoms of relapse/recurrence of depression while not on medication~5. Age 21-64, inclusive~6. Women must use a medically acceptable form of contraception (steroidal contraceptive, double-barrier, or intra-uterine device) during the entire study period, or: be surgically sterilized, post-menopausal, agree to use double-barrier contraception throughout the study period, or must have a negative urine pregnancy test prior to randomization.~7. Subject must be stabilized on all ongoing long-term medication therapy for at least 28 days prior to screening visit.~MAJOR EXCLUSION CRITERIA:~1. Severity of depressive episode had been rated as severe or severe with psychotic features.~2. History of a suicide attempt or suicidal ideation.~3. History of mania, manic episode or bipolar disease.~4. Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days preceding randomization.~5. Use of prescription and non-prescription sedative drugs given for the purpose of sleep induction or to relieve jet lag~6. Any abnormal pre-study laboratory values that require clinical intervention~7. Prior failure to respond to escitalopram therapy for depression~8. Current depressive episode requiring inpatient hospitalization.~9. Shift work or requirement for a regular change in sleep schedule by at least six hours within the previous 28 days.~10. History of drug addiction, alcoholism, or drug abuse.~11. A positive urine drug screen for medication that would interfere with the assessment of the study medication.~12. Known allergy to zolpidem, escitalopram or any of their excipients~13. History of sleep apnea~14. History of myasthenia gravis~15. The presence of any untreated or uncompensated clinically significant renal, endocrine, gastrointestinal, hepatic, respiratory, cardiovascular, other neurologic, hematologic, oncologic, immunologic, cerebrovascular disease or malignancy.~16. Pregnant or breastfeeding~17. Subject is participating in another clinical trial, or has completed another clinical trial within 28 days prior to screening.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).